phone

United States Drug Delivery Devices Market Outlook to 2023 - Central Venous Catheters, Infusion Systems, Needle Free Injections and Metered Dose Inhaler Devices

  • Published Date: 01 Aug 2017
  • Number of Pages: 980
  • Category: Healthcare and Medical
  • Country: United States of America
United States Drug Delivery Devices Market Outlook to 2023 - Central Venous Catheters, Infusion Systems, Needle Free Injections and Metered Dose Inhaler Devices

Summary

GlobalDatas new report, "United States Drug Delivery Devices Market Outlook to 2023", provides key market data on the United States Drug Delivery Devices market. The report provides value, in millions of US dollars and volume (in units) within market categories - Central Venous Catheters, Needle Free Injections, Infusion Systems and Metered Dose Inhaler Devices.

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

- Market size and company share data for Drug Delivery Devices market categories - Central Venous Catheters, Needle Free Injections, Infusion Systems and Metered Dose Inhaler Devices.
- Annualized market revenues (USD million) and volume (units) data for each of the market categories. Data is provided from 2009 to 2016 and forecast to 2023.
- 2016 company shares and distribution shares data for each of the market categories.
- Global corporate-level profiles of key companies operating within the United States Drug Delivery Devices market.
- Key players covered include GlaxoSmithKline Plc, AstraZeneca Plc, Hospira Inc, Becton Dickinson and Co, Boehringer Ingelheim GmbH, Baxter International Inc, Medtronic plc and others.

Reasons to buy

- Develop business strategies by identifying the key market categories poised for strong growth in the future.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the market.
- Develop investment strategies by identifying the key market categories expected to register strong growth in the near future.
- What are the key distribution channels and whats the most preferred mode of product distribution - Identify, understand and capitalize.
Publisher Name : GlobalData

2 Introduction 9
2.1 What Is This Report About? 9
2.2 Drug Delivery Devices Market Segmentation 9
2.3 Definitions of Markets Covered in the Report 10
3 Drug Delivery Devices Market, United States 13
3.1 Drug Delivery Devices Market, United States, Revenue ($m), 2009-2023 13
3.2 Drug Delivery Devices Market, United States, Revenue Mix ($m), 2016 15
3.3 Drug Delivery Devices Market, United States, Category Contribution by Revenue ($m), 2016 16
3.4 Drug Delivery Devices Market, United States, Category Comparison by Revenue ($m), 2009-2023 17
3.5 Drug Delivery Devices Market, United States, Revenue ($m), 2009-2016 19
3.6 Drug Delivery Devices Market, United States, Revenue ($m), 2016-2023 21
3.7 Drug Delivery Devices Market, United States, Volume (Units), 2009-2023 23
3.8 Drug Delivery Devices Market, United States, Volume (Units), 2009-2016 25
3.9 Drug Delivery Devices Market, United States, Volume (Units), 2016-2023 27
3.10 Drug Delivery Devices Market, United States, Company Share by Revenue ($m), 2016 29
4 Central Venous Catheters Market, United States 31
4.1 Central Venous Catheters Market, United States, Revenue Mix ($m), 2016 31
4.2 Central Venous Catheters Market, United States, Segment Contribution (%), 2016 32
4.3 Central Venous Catheters Market, United States, Revenue ($m), 2009-2016 33
4.4 Central Venous Catheters Market, United States, Revenue ($m), 2016-2023 35
4.5 Central Venous Catheters Market, United States, Volume (Units), 2009-2016 37
4.6 Central Venous Catheters Market, United States, Volume (Units), 2016-2023 39
4.7 Central Venous Catheters Market, United States, Distribution Share by Revenue ($m), 2015-2016 41
4.8 Central Venous Catheters Market, United States, Company Share by Revenue ($m), 2016 42
5 Infusion Systems Market, United States 44
5.1 Infusion Systems Market, United States, Revenue Mix ($m), 2016 44
5.2 Infusion Systems Market, United States, Segment Contribution (%), 2016 45
5.3 Infusion Systems Market, United States, Revenue ($m), 2009-2016 46
5.4 Infusion Systems Market, United States, Revenue ($m), 2016-2023 48
5.5 Infusion Systems Market, United States, Volume (Units), 2009-2016 58
5.6 Infusion Systems Market, United States, Volume (Units), 2016-2023 60
5.7 Infusion Systems Market, United States, Distribution Share by Revenue ($m), 2015-2016 70
5.8 Infusion Systems Market, United States, Company Share by Revenue ($m), 2016 71
6 Needle Free Injections Market, United States 73
6.1 Needle Free Injections Market, United States, Revenue ($m), 2009-2016 73
6.2 Needle Free Injections Market, United States, Revenue ($m), 2016-2023 74
6.3 Needle Free Injections Market, United States, Volume (Units), 2009-2016 75
6.4 Needle Free Injections Market, United States, Volume (Units), 2016-2023 76
6.5 Needle Free Injections Market, United States, Distribution Share by Revenue ($m), 2015-2016 77
6.6 Needle Free Injections Market, United States, Company Share by Revenue ($m), 2016 78
7 Metered Dose Inhaler Devices Market, United States 80
7.1 Metered Dose Inhaler Devices Market, United States, Revenue ($m), 2009-2016 80
7.2 Metered Dose Inhaler Devices Market, United States, Revenue ($m), 2016-2023 81
7.3 Metered Dose Inhaler Devices Market, United States, Volume (Units), 2009-2016 82
7.4 Metered Dose Inhaler Devices Market, United States, Volume (Units), 2016-2023 83
7.5 Metered Dose Inhaler Devices Market, United States, Distribution Share by Revenue ($m), 2015-2016 84
7.6 Metered Dose Inhaler Devices Market, United States, Company Share by Revenue ($m), 2016 85
8 Overview of Key Companies in United States, Drug Delivery Devices Market 87
8.1 GlaxoSmithKline Plc 87
8.2 Teleflex Inc 87
8.3 AstraZeneca Plc 87
8.4 C. R. Bard Inc 88
8.5 Hospira Inc 88
8.6 Becton Dickinson and Co 88
8.7 Edwards Lifesciences Corp 88
8.8 Baxter International Inc 89
8.9 Boehringer Ingelheim GmbH 89
8.10 Medtronic Plc 89
8.11 Smiths Medical 90
8.12 B. Braun Melsungen AG 90
8.13 Pfizer Inc 90
8.14 Fresenius Kabi AG 91
8.15 Merck & Co Inc 91
9 Drug Delivery Devices Market Pipeline Products 92
10 Financial Deals Landscape 98
10.1 Acquisition 98
10.2 Asset Transactions 105
10.3 Debt Offerings 107
10.4 Equity Offerings 147
10.5 Merger 223
10.6 Partnerships 225
10.7 Private Equity 252
10.8 Venture Financing 256
11 Recent Developments 285
11.1 Corporate Communications 285
11.2 Financial Announcements 418
11.3 Government and Public Interest 875
11.4 Legal And Regulatory 881
11.5 Other Significant Developments 896
11.6 Product News 919
11.7 Strategy And Business Planning 942
12 Appendix 954
12.1 Research Methodology 955
12.2 GlobalData Consulting 957
12.3 Contact Us 958
12.4 Disclaimer 958

List Of Tables


Table 1: Drug Delivery Devices Market, United States, Revenue ($m), USD Constant, 2009-2023 36
Table 2: Drug Delivery Devices Market, United States, Category Contribution by Revenue ($m), 2016 38
Table 3: Drug Delivery Devices Market, United States, Category Comparison by Revenue ($m), 2009-2023 40
Table 4: Drug Delivery Devices Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 42
Table 5: Drug Delivery Devices Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 44
Table 6: Drug Delivery Devices Market, United States, Volume (Units), 2009-2023 46
Table 7: Drug Delivery Devices Market, United States, Volume (Units), Historic, 2009-2016 48
Table 8: Drug Delivery Devices Market, United States, Volume (Units), Forecast, 2016-2023 50
Table 9: Drug Delivery Devices Market, United States, Company Share by Revenue ($m), USD Constant, 2016 52
Table 10: Central Venous Catheters Market, United States, Segment Contribution (%), 2016 54
Table 11: Central Venous Catheters Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 56
Table 12: Central Venous Catheters Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 58
Table 13: Central Venous Catheters Market, United States, Volume (Units), Historic, 2009-2016 60
Table 14: Central Venous Catheters Market, United States, Volume (Units), Forecast, 2016-2023 62
Table 15: Central Venous Catheters Market, United States, Distribution Share by Revenue ($m), USD Constant, 2015-2016 63
Table 16: Central Venous Catheters Market, United States, Company Share by Revenue ($m), USD Constant, 2016 65
Table 17: Infusion Systems Market, United States, Segment Contribution (%), 2016 67
Table 18: Infusion Systems Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 69
Table 19: Infusion Systems Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 71
Table 20: Ambulatory Infusion Pumps Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 73
Table 21: Syringe Pumps Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 75
Table 22: Ambulatory Infusion Pumps Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 77
Table 23: Syringe Pumps Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 79
Table 24: Infusion Systems Market, United States, Volume (Units), Historic, 2009-2016 81
Table 25: Infusion Systems Market, United States, Volume (Units), Forecast, 2016-2023 83
Table 26: Ambulatory Infusion Pumps Market, United States, Volume (Units), Historic, 2009-2016 85
Table 27: Syringe Pumps Market, United States, Volume (Units), Historic, 2009-2016 87
Table 28: Ambulatory Infusion Pumps Market, United States, Volume (Units), Forecast, 2016-2023 89
Table 29: Syringe Pumps Market, United States, Volume (Units), Forecast, 2016-2023 91
Table 30: Infusion Systems Market, United States, Distribution Share by Revenue ($m), USD Constant, 2015-2016 92
Table 31: Infusion Systems Market, United States, Company Share by Revenue ($m), USD Constant, 2016 94
Table 32: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 95
Table 33: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 96
Table 34: Needle Free Injections Market, United States, Volume (Units), Historic, 2009-2016 97
Table 35: Needle Free Injections Market, United States, Volume (Units), Forecast, 2016-2023 98
Table 36: Needle Free Injections Market, United States, Distribution Share by Revenue ($m), USD Constant, 2015-2016 99
Table 37: Needle Free Injections Market, United States, Company Share by Revenue ($m), USD Constant, 2016 101
Table 38: Metered Dose Inhaler Devices Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 102
Table 39: Metered Dose Inhaler Devices Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 103
Table 40: Metered Dose Inhaler Devices Market, United States, Volume (Units), Historic, 2009-2016 104
Table 41: Metered Dose Inhaler Devices Market, United States, Volume (Units), Forecast, 2016-2023 105
Table 42: Metered Dose Inhaler Devices Market, United States, Distribution Share by Revenue ($m), USD Constant, 2015-2016 106
Table 43: Metered Dose Inhaler Devices Market, United States, Company Share by Revenue ($m), USD Constant, 2016 108
Table 44: Drug Delivery Devices Market Pipeline Products 114
Table 45: Peaceful Union Acquires Sharklet Technologies 120
Table 46: Serum Institute of India Acquires Nanotherapeutics for USD78.2 Million 121
Table 47: Becton, Dickinson to Acquire C. R. Bard for USD24 Billion 122
Table 48: Shire May Acquire Radius Health 124
Table 49: PixarBio Terminates Acquisition of InVivo Therapeutics for USD77 Million 125
Table 50: Merck and Allergan May Acquire Biogen 126
Table 51: ICU Medical Acquires Hospira Infusion Systems Business from Pfizer 127
Table 52: PAVmed Raises USD5 Million in Private Placement of Notes and Warrants 129
Table 53: Becton, Dickinson to Raise USD725 Million in Public Offering of 2.133% Notes Due 2019 130
Table 54: Becton, Dickinson to Raise USD1 Billion in Public Offering of 2.404% Notes Due 2020 131
Table 55: Becton, Dickinson to Raise USD1.8 Billion in Public Offering of 2.894% Notes Due 2022 132
Table 56: Becton, Dickinson to Raise USD500 Million in Public Offering of Floating Rate Notes Due 2022 133
Table 57: Becton, Dickinson to Raise USD1.75 Billion in Public Offering of 3.363% Notes Due 2024 134
Table 58: Becton, Dickinson to Raise USD2.4 Billion in Public Offering of 3.7% Notes Due 2027 135
Table 59: Becton, Dickinson to Raise USD1.5 Billion in Public Offering of 4.669% Notes Due 2047 136
Table 60: Becton, Dickinson to Raise USD788 Million in Public Offering of 0.368% Notes Due 2019 137
Table 61: Skinvisible Raises USD0.2 Million in Issue of 10% Convertible Promissory Notes Due 2018 138
Table 62: Pfizer Raises USD1.3 Billion in Public Offering of Notes Due 2019 139
Table 63: Pfizer Raises USD1.06 Billion in Public Offering of Notes Due 2020 141
Table 64: Pfizer Raises USD1.06 Billion in Public Offering of 0.25% Notes Due 2022 143
Table 65: Pfizer Raises USD793.5 Million in Public Offering of 1% Notes Due 2027 145
Table 66: Pfizer Raises USD1.06 Billion in Private Placement of 4.2% Notes Due 2047 147
Table 67: Premier Biomedical Raises Funds in Third Tranche of Private Placement of 10% Notes Due 2016 149
Table 68: Catalent Prices Private Placement of 4.75% Notes Due 2024 for USD404.5 Million 150
Table 69: Becton Dickinson Prices Public Offering of 1% Notes Due 2022 for USD500 Million 151
Table 70: Becton Dickinson Prices Public Offering of 1.9% Notes Due 2026 for USD500 Million 153
Table 71: Pfizer Raises USD1 Billion in Public Offering of 1.7% Notes Due 2019 155
Table 72: Pfizer Raises USD1 Billion in Public Offering of 2.2% Notes Due 2021 157
Table 73: Pfizer Raises USD1.8 Billion in Public Offering of 3% Notes Due 2026 159
Table 74: Pfizer Raises USD1 Billion in Public Offering of 4% Notes Due 2036 161
Table 75: Pfizer Raises USD1.3 Billion in Public Offering of 4.125% Notes Due 2046 163
Table 76: Merck Raises USD544 Million in Public Offering of 1.375% Notes Due 2036 165
Table 77: Merck Raises USD544 Million in Public Offering of 0.5% Notes Due 2024 167
Table 78: KalVista Pharma Plans to Raise up to USD6 Million in Public Offering of Shares 169
Table 79: Clearside Biomedical Plans to Raise up to USD50 Million in Public Offering of Shares 170
Table 80: Delcath Systems to Raise USD2.4 Million in Private Placement of Series B Preferred Shares 171
Table 81: MannKind Plans to Raise Funds through Private Placement of Shares upon Exercise of Warrants 172
Table 82: PhaseRx Plans to Raise up to USD15 Million in Public Offering of Shares and Warrants 173
Table 83: EyeGate Pharma Raises USD10 Million in Public Offering of Shares and Warrants 174
Table 84: Zynerba Pharma Plans to Raise up to USD50 Million in Public Offering 176
Table 85: Savara Raises USD42.9 Million in Public Offering of Shares 177
Table 86: Premier Biomedical to Raise Funds through Public Offering of Shares 179
Table 87: MRI Interventions Raises USD13.3 Million in Private Placement of Units 180
Table 88: Alnylam Pharma Prices Public Offering of Shares for USD359.4 Million 181
Table 89: Corium International Raises USD40.3 Million in Public Offering of Shares 183
Table 90: Halozyme Therapeutics Raises USD143.8 Million in Public Offering of Shares 185
Table 91: Bellerophon Therapeutics to Raise USD30 Million in Private Placement of Shares 187
Table 92: Becton Dickinson Raises USD2.47 Billion in Public Offering of Shares 188
Table 93: Becton Dickinson Raises USD2.47 Billion in Public Offering of Depositary Shares 190
Table 94: Savara to Raise up to USD18 Million in Public Offering of Shares 192
Table 95: BioPharmX Raises USD5 Million in Private Placement of Shares and Warrants 193
Table 96: NanoCarrier Agrees to Invest in Tocagen 194
Table 97: Capnia Files Registration Statement for Secondary Offering of Shares 195
Table 98: Adamis Pharma Raises USD17.3 Million in Public Offering of Shares 196
Table 99: AngioDynamics Prices Public Offering of Shares for USD38 Million 198
Table 100: Tocagen Raises USD97.8 Million in IPO 199
Table 101: Premier Biomedical Raises USD0.3 Million in First Tranche of Private Placement of Shares and Warrants 201
Table 102: Catalyst Biosciences Raises USD20.7 Million in Public Offering of Units 202
Table 103: Alliqua BioMedical Raises USD2.8 Million in Private Placement of Shares 204
Table 104: Evoke Pharma Raises USD8 Million in Public Offering of Shares 205
Table 105: Windtree Therapeutics Raises USD10.5 Million in Private Placement of Units 207
Table 106: pSivida Plans to Raise Upto USD20 Million in Public Offering of Shares 209
Table 107: Galena Biopharma Raises Up to USD15.5 Million in Public Offering of Shares and Warrants 210
Table 108: Valeritas Files Registration Statement for IPO for up to USD50 Million 212
Table 109: PAVmed to Raise USD10.4 Million in Private Placement of Shares upon Exercise of Warrants 214
Table 110: Premier Biomedical Withdraws Public Offering of Shares 215
Table 111: PAVmed Raises Additional Funds in Second and Final Tranche of Private Placement of Units 216
Table 112: Corium International Raises USD20 Million in Public Offering of Shares 217
Table 113: Nu-Med Plus Raises USD0.3 Million in Private Placement of Shares 218
Table 114: Capnia Raises USD2 Million in First Tranche of Private Placement of Shares 219
Table 115: PAVmed Raises USD1.5 Million in First Tranche of Private Placement of Units 220
Table 116: Zynerba Pharma Announces Underwriters Exercise of Over-Allotment of Public Offering of Shares 221
Table 117: Heron Therapeutics Raises USD172.6 Million in Public Offering of Shares 223
Table 118: Braeburn Pharma to Raise USD40 Million in Private Placement of Shares 225
Table 119: Capnia Raises USD10 Million in Private Placement of Shares 226
Table 120: Milestone Scientific Completes Underwriters Partial Exercise of Over-Allotment Option of Public Offering of Shares 227
Table 121: AngioDynamics Prices Public Offering of Shares for USD32 Million 229
Table 122: PAVmed to Raise USD5.3 Million in Private Placement of Shares upon Exercise of Warrants 231
Table 123: ConvaTec Raises USD1.8 Billion in IPO 232
Table 124: Galena Biopharma to Raise Funds in Public Offering of Shares 233
Table 125: BioPharmX Raises USD12.5 Million in Public Offering of Units and Warrants 234
Table 126: Delcath Systems Prices Public Offering Shares and Warrants for USD1.3 Million 236
Table 127: T2 Biosystems Raises USD40 Million in Private Placement of Shares 237
Table 128: Intarcia Therapeutics Raises USD215 Million in First Tranche of Private Placement of Shares 238
Table 129: Catalent to Raise Funds through Public Offering of Shares 239
Table 130: MRI Interventions to Raise USD4.3 Million in Private Placement of Units 240
Table 131: BioMarin Pharma Prices Public Offering of Shares for USD720 Million 241
Table 132: Osprey Medical to Raise USD0.8 Million in Share Purchase Plan of CDIs 242
Table 133: Adamis Pharma to Raise USD11 Million in Private Placement of Units 243
Table 134: Dipexium Pharma Merges with PLx Pharma 245
Table 135: Infuseon Therapeutics Enters into Agreement with Oncosynergy 247
Table 136: Nobilis Therapeutics Enters into Agreement with Submersible Systems 248
Table 137: MannKind and One Drop to Enter into Agreement 249
Table 138: TWi Pharma Enters into Agreement with Intech Biopharm 250
Table 139: United Therapeutics Enters into Licensing Agreement with Respira Therapeutics 251
Table 140: Audax Medical Enters into Licensing Agreement with Northeastern University 252
Table 141: CannaRoyalty Enters into Licensing Agreement with NuTrae 253
Table 142: ViaCyte Enters into Research Agreement with W. L. Gore & Associates 254
Table 143: OncoSec Medical Enters into Agreement with Inhibrx 255
Table 144: Northwell Health Enters into Partnership with United Therapeutics 256
Table 145: PharmaJet Enters into Agreement with Serum Institute of India 257
Table 146: Aequus Pharma to Enter into Licensing Agreement with Transdermal Research Pharm Labs 258
Table 147: Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 259
Table 148: Hikma Pharma Enters into Licensing Agreement with Orion 261
Table 149: A1 Group Enters into Licensing and Distribution Agreement ?with Novaceutical Sciences 262
Table 150: 3M Drug Delivery Systems Partners with Panacea Pharma 263
Table 151: Neuronex Enters Into Licensing Agreement With SK Biopharmaceuticals For DZNS Technology 264
Table 152: Pfizer Terminates its Licensing Agreement with pSivida 265
Table 153: Iatric Systems Enters into Agreement with Hospira 266
Table 154: Tepha Enters into Agreement with Metabolix 267
Table 155: Bayer Enters into Licensing Agreement with DelSiTech 268
Table 156: ALZYN Enters into Licensing Agreement with Transdermal Delivery Solutions 269
Table 157: Themis Medicare Enters into Agreement with Nevakar 270
Table 158: Qualcomm Partners with Boehringer Ingelheim Pharma 271
Table 159: SkinJect Enters into Licensing Agreement with University of Pittsburgh 272
Table 160: BioCorRx Enters into Licensing Agreement with Therakine 273
Table 161: 3i Group to Invest USD136 Million in Cirtec Medical Systems from Century Park Capital Partners 274
Table 162: AGIC Capital to Acquire Ritedose From Olympus Partners 275
Table 163: 410 Medical Raises USD3.3 Million in Series A Financing 276
Table 164: Mentor Capital Invests USD1 Million in GW Pharma 277
Table 165: Otomagnetics Raises USD0.3 Million in Venture Financing 278
Table 166: Pharmajet Raises USD3 Million in Venture Financing 279
Table 167: 410 Medical Raises Additional USD2.1 Million in Series A Financing 280
Table 168: NexGen Medical Systems Raises USD1.5 Million in Venture Financing 281
Table 169: Xeris Pharma Raises Additional USD30 Million in Series C Financing 282
Table 170: Respira Therapeutics to Raise Funds through Series B Preferred Stock Financing 284
Table 171: Ivenix Raises USD50 Million in First Tranche of Equity Financing 285
Table 172: Ivenix Raises USD10 Million in Venture Financing 286
Table 173: Surefire Medical Raises USD12.8 Million in First Round of Series D Financing 287
Table 174: Unilife Raises USD5 Million in Venture Financing 288
Table 175: iVeena Delivery Systems to Raise USD1 Million in Venture Financing 289
Table 176: NapaJen Pharma to Raise Funds in Equity Financing 290
Table 177: Impel NeuroPharma Raises USD21 Million in First Tranche of Series C Financing 291
Table 178: Tocagen Raises USD2.73 Million in Venture Financing 292
Table 179: Impel NeuroPharma Raises USD22.3 Million in Venture Financing 293
Table 180: Unilife Raises USD10.6 Million in Financing Round 294
Table 181: Propeller Health Raises USD21.5 Million in Series C Financing 295
Table 182: BioQ Pharma Raises USD15 Million in Financing Round 296
Table 183: Enable Injections Raises USD30 Million in Series A Financing 297
Table 184: QuiO Technologies Raises USD1.05 Million in Seed Financing 299
Table 185: Impel NeuroPharma Raises USD0.08 Million in Venture Financing 300
Table 186: Kaio Therapy Raises USD0.2 Million in Venture Financing 301
Table 187: Credence MedSystems Raises USD15 Million in Series A Financing 302
Table 188: Chrono Therapeutics Raises USD47.6 Million in Series B Financing 303
Table 189: Enable Injections Raises USD10 Million in Venture Financing 305
Table 190: Fe3 Medical Raises Additional USD3.5 Million in Series B Financing Round 306

List Of Figures


Figure 1: Drug Delivery Devices Market, United States, Revenue ($m), USD Constant, 2009-2023 35
Figure 2: Drug Delivery Devices Market, United States, Revenue Mix ($m), 2016 37
Figure 3: Drug Delivery Devices Market, United States, Category Contribution (%), 2016 38
Figure 4: Drug Delivery Devices Market, United States, Category Comparison by Revenue ($m), 2009-2023 39
Figure 5: Drug Delivery Devices Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 41
Figure 6: Drug Delivery Devices Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 43
Figure 7: Drug Delivery Devices Market, United States, Volume (Units), 2009-2023 45
Figure 8: Drug Delivery Devices Market, United States, Volume (Units), Historic, 2009-2016 47
Figure 9: Drug Delivery Devices Market, United States, Volume (Units), Forecast, 2016-2023 49
Figure 10: Drug Delivery Devices Market, United States, Company Share (%) 2016 51
Figure 11: Central Venous Catheters Market, United States, Revenue Mix ($m), 2016 53
Figure 12: Central Venous Catheters Market, United States, Segment Contribution (%), 2016 54
Figure 13: Central Venous Catheters Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 55
Figure 14: Central Venous Catheters Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 57
Figure 15: Central Venous Catheters Market, United States, Volume (Units), Historic, 2009-2016 59
Figure 16: Central Venous Catheters Market, United States, Volume (Units), Forecast, 2016-2023 61
Figure 17: Central Venous Catheters Market, United States, Company Share (%) 2016 64
Figure 18: Infusion Systems Market, United States, Revenue Mix ($m), 2016 66
Figure 19: Infusion Systems Market, United States, Segment Contribution (%), 2016 67
Figure 20: Infusion Systems Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 68
Figure 21: Infusion Systems Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 70
Figure 22: Ambulatory Infusion Pumps Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 72
Figure 23: Syringe Pumps Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 74
Figure 24: Ambulatory Infusion Pumps Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 76
Figure 25: Syringe Pumps Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 78
Figure 26: Infusion Systems Market, United States, Volume (Units), Historic, 2009-2016 80
Figure 27: Infusion Systems Market, United States, Volume (Units), Forecast, 2016-2023 82
Figure 28: Ambulatory Infusion Pumps Market, United States, Volume (Units), Historic, 2009-2016 84
Figure 29: Syringe Pumps Market, United States, Volume (Units), Historic, 2009-2016 86
Figure 30: Ambulatory Infusion Pumps Market, United States, Volume (Units), Forecast, 2016-2023 88
Figure 31: Syringe Pumps Market, United States, Volume (Units), Forecast, 2016-2023 90
Figure 32: Infusion Systems Market, United States, Company Share (%) 2016 93
Figure 33: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 95
Figure 34: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 96
Figure 35: Needle Free Injections Market, United States, Volume (Units), Historic, 2009-2016 97
Figure 36: Needle Free Injections Market, United States, Volume (Units), Forecast, 2016-2023 98
Figure 37: Needle Free Injections Market, United States, Company Share (%) 2016 100
Figure 38: Metered Dose Inhaler Devices Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 102
Figure 39: Metered Dose Inhaler Devices Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 103
Figure 40: Metered Dose Inhaler Devices Market, United States, Volume (Units), Historic, 2009-2016 104
Figure 41: Metered Dose Inhaler Devices Market, United States, Volume (Units), Forecast, 2016-2023 105
Figure 42: Metered Dose Inhaler Devices Market, United States, Company Share (%) 2016 107

United States mobile application testing (MAT) services market is projected to grow at a CAGR of over 11% by 2022, on the back of increasing number of smartphone and internet

View Report

Savory Baked Goods (Savory & Deli Foods) Market in the United States of America - Outlook to 2021: Market Size, Growth and Forecast Analytics Savoury Baked Goods includes all Croque Monsieurs

View Report

Savory Baked Goods (Savory & Deli Foods) Market in the United Kingdom - Outlook to 2021: Market Size, Growth and Forecast Analytics Savoury Baked Goods includes all Croque Monsieurs (a grilled

View Report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports